Related Experiment Video
Updated: Jul 8, 2026
06:19
Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
Subconjunctival bevacizumab injection for corneal neovascularization
Irit Bahar1, Igor Kaiserman, Penny McAllum
1Department of Ophthalmology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. iritbahar@yahoo.com
Cornea
|January 25, 2008
Summary
Subconjunctival bevacizumab injections effectively reduced corneal neovascularization in patients. This treatment was well-tolerated, showing partial regression of blood vessels in the cornea with no significant adverse events.
Area of Science:
- Ophthalmology
- Vascular Biology
Background:
- Corneal neovascularization (CNV) poses a significant risk to vision.
- Anti-VEGF therapies are explored for managing CNV.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of subconjunctival bevacizumab for treating corneal neovascularization.
- To assess the impact of bevacizumab on the extent and density of corneal vessels.
Main Methods:
- Retrospective chart review of 10 patients with CNV receiving subconjunctival bevacizumab (2.5 mg/0.1 mL).
- Corneal photographs were assessed by masked observers for vessel density and extent.
- Digital image analysis quantified the percentage of corneal surface covered by neovascularization.
Main Results:
- Subconjunctival bevacizumab demonstrated a significant reduction in corneal neovascularization extent (P=0.008) and density (P=0.007).
- On average, bevacizumab decreased corneal neovascularization by 29%.
- No significant ocular or systemic adverse events were reported during the follow-up period.
Conclusions:
- Subconjunctival bevacizumab is a safe and well-tolerated treatment for corneal neovascularization.
- The treatment is associated with partial regression of corneal vascularization.
- Further research may explore long-term outcomes and optimal dosing.
Related Concept Videos
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...